


## Afloqualone

<b>Cat. No.:</b>	HY-B1833		
<b>CAS No.:</b>	56287-74-2		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>14</sub> FN <sub>3</sub> O		
<b>Molecular Weight:</b>	283.3		
<b>Target:</b>	GABA Receptor		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 33 mg/mL (116.48 mM)

\* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.5298 mL	17.6491 mL	35.2983 mL
	5 mM	0.7060 mL	3.5298 mL	7.0597 mL
	10 mM	0.3530 mL	1.7649 mL	3.5298 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Afloqualone (HQ-495) is a GABAergic agent and has agonist activity at the  $\beta$  subtype of the GABA $\alpha$  receptor. Afloqualone has antiveriginous effects thought to be attributable to the increased sensitivity of GABA receptors of the LVN neuron site<sup>[1]</sup>.

### REFERENCES

[1]. T Ochiai, et al. Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity. Jpn J Pharmacol. 1982 Jun;32(3):427-38.

[2]. Y Kudo, et al. Effects of afloqualone on vestibular nystagmus and the lateral vestibular nucleus. Jpn J Pharmacol. 1989 Aug;50(4):515-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA